Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sunesis Pharmaceutic (SNSS)

Sunesis Pharmaceutic (SNSS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors

Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto brings over 20 years of oncology drug development...

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President of Finance and Corporate Development, will present at the Wells Fargo Healthcare...

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

SNSS : 0.59 (-4.84%)
Sunesis: 2Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Wednesday reported a loss of $6.2 million in its second quarter.

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2019. Loss from operations for the three and six months ended June 30, 2019 was $6.2 million...

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2019 Financial Results and Recent Highlights

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, August 7, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results...

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

SNSS : 0.59 (-4.84%)
Sunesis Announces Pricing of $25 Million Offering of Securities

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible...

SNSS : 0.59 (-4.84%)
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock...

WFC : 49.65 (-0.92%)
SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President,...

SNSS : 0.59 (-4.84%)
Sunesis: 1Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Wednesday reported a loss of $5.9 million in its first quarter.

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights

Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort

SNSS : 0.59 (-4.84%)
What's in the Cards for Sunesis (SNSS) This Earnings Season?

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

SNSS : 0.59 (-4.84%)
BIIB : 227.84 (+0.79%)
GILD : 65.44 (+0.21%)
TAK : 17.60 (-0.17%)
Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for...

SNSS : 0.59 (-4.84%)
Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank. The new agreement allows the company to retire its existing...

SNSS : 0.59 (-4.84%)
Biotechs Strive to Provide Patients With More Affordable Treatment Options

The American Cancer Society estimated that in 1991, cancer deaths peaked at 215 deaths per 100,000 persons. As of 2014, the rate dropped significantly to just 161 deaths per 100,000 persons, representing...

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
ATOS : 1.79 (+2.29%)
AGEN : 2.60 (-1.52%)
SNSS : 0.59 (-4.84%)
OMED : 0.93 (+4.49%)
Investor Expectations to Drive Momentum within Avalara, Sunesis Pharmaceuticals, NexPoint Residential Trust, Ferroglobe, China Online Education Group, and S&W Seed -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Avalara, Inc. (NYSE:AVLR), Sunesis...

AVLR : 68.07 (-8.30%)
SNSS : 0.59 (-4.84%)
NXRT : 47.08 (-4.98%)
GSM : 0.75 (-2.60%)
COE : 7.00 (+1.16%)
SANW : 2.37 (+0.84%)
Biotech Firms Strive to Combat the Growing Burden of Diseases With Innovative Technologies

NEW YORK, April 4, 2019 The global burden of diseases continues to grow each year, despite various ongoing medical advancements. In 2017, the Institute for Health Metrics and Evaluation (IHME) said in...

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
ARQL : 8.99 (+4.05%)
SRNE : 1.73 (+7.45%)
SNSS : 0.59 (-4.84%)
ONCS : 2.04 (-0.97%)
Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham...

SNSS : 0.59 (-4.84%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.10 , AIZ +0.02 , SBAC -6.19 , SO +0.44 , WELL -0.48
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar